Tissue Repair & Musculoskeletal Care
Selected OWM protocols discuss peptides alongside PRP, prolotherapy, cellular preparations, or nerve hydrodissection. Their proposed addition requires separate consideration from the injection procedure itself.
BPC-157
BPC-157 is investigated for effects on tissue repair, including tendon, ligament, and gastrointestinal tissues. Human evidence remains limited, and it is not an established treatment for structural healing.
Thymosin Beta-4 & TB-500
Thymosin beta-4 is involved in cellular processes associated with movement and repair. Products marketed as TB-500 may differ from full-length thymosin beta-4 and should not be treated as interchangeable preparations.
The “Wolverine Stack”
This name commonly describes a combination of BPC-157 and TB-500. It is a marketing term rather than a validated treatment protocol, and combining the compounds does not establish improved injury recovery or postoperative healing.
CJC-1295 & Ipamorelin
These compounds influence growth hormone signaling. Their proposed use before regenerative procedures requires assessment of endocrine effects and risks; improved stem cell activity or treatment outcomes have not been established.
GHK-Cu
GHK-Cu is a copper-binding peptide studied in skin and tissue biology. Evidence and safety depend on the formulation and administration route, with topical cosmetic use distinct from injection-based treatment.
Cognitive Health & Sleep
Cerebrolysin
Cerebrolysin is a peptide mixture investigated in neurological conditions and described within our Brain Spa Biohacker protocol. It is not FDA-approved in the United States, and its proposed use requires separate clinical and regulatory review.
Selank & Semax
These synthetic peptides have been studied for effects on nervous system signaling, anxiety, and cognition. Evidence is insufficient to present them as established treatments for anxiety, sleep disturbance, or impaired memory.
BDNF & Dihexa Protocols
Brain-derived neurotrophic factor, or BDNF, is a protein involved in neural function. Its biological role does not establish an effective treatment through direct administration. Dihexa is an investigational compound studied for effects on neural signaling, with substantial gaps in human safety and efficacy information.
Delta Sleep-Inducing Peptide
DSIP is investigated in relation to sleep and stress responses. It should not be presented as a proven method of restoring deep sleep or treating insomnia.
Metabolic Health & Body Composition
Semaglutide & Tirzepatide
Approved formulations of these peptide-based medications have specific indications for diabetes or weight management. We assess eligibility and coordinate treatment with nutrition, physical activity, and monitoring.
Retatrutide & Cagrilintide
These investigational compounds are distinct from approved metabolic medications. They are not routine prescription alternatives, and FDA states that they cannot be used in compounding under federal law.
Tesamorelin & AOD-9604
Tesamorelin is approved for excess abdominal fat in adults with HIV-associated lipodystrophy, rather than general weight loss. AOD-9604 remains an unapproved compound with limited evidence for weight-management benefits and unresolved safety considerations.
MOTS-C & SS-31
MOTS-C is investigated for its role in metabolic signaling, while human treatment evidence remains limited.
SS-31, also known as elamipretide, targets mitochondrial pathways. An approved elamipretide formulation has a specific indication for improving muscle strength in patients with Barth syndrome weighing at least 30 kilograms; that approval does not establish benefits for general energy enhancement or longevity.
Immune & Environmental Illness Protocols
Thymosin Alpha-1
Thymosin alpha-1 is studied for immune-modulating effects. Its proposed role must be assessed for the specific condition rather than described broadly as boosting immunity or treating viral reactivation.
LL-37
LL-37 is a naturally occurring antimicrobial peptide with roles in immune signaling. These functions do not establish that administering it treats chronic infections, and important human safety questions remain.
Vasoactive Intestinal Peptide
VIP is described within the Shoemaker approach to Chronic Inflammatory Response Syndrome. We review its proposed role in the context of a comprehensive assessment, recognizing that this protocol does not establish VIP as a proven treatment for mold-related neurological injury.
Stem Cell Activator IV
This name describes a six-peptide formulation within the supplied OWM protocols. Its ingredients, doses, evidence, and regulatory status require individual review; the name alone does not establish systemic stem cell activation or anti-aging benefits.
Personalized Planning & Monitoring
Our consultation considers whether a peptide-based treatment has an appropriate clinical role and whether established alternatives are available. When combinations are proposed, we assess the rationale and cumulative risks rather than assuming that a “stack” improves effectiveness.
Potential concerns include immune reactions, impurities, medication interactions, and compound-specific effects. Follow-up is guided by the diagnosis and may include symptoms, relevant laboratory markers, and adverse-effect monitoring.
